Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621880 | 0.89 | MAPK8 (0.38) | NPC1RAB9AKDM4EMAPK8MAPK10 | |
| SCHEMBL11957018 | 0.84 | GPR119 (0.46) | NPC1RAB9AKDM4EOGAGPR119 | |
| SCHEMBL18714938 | 0.81 | HRH3 (0.39) | NPC1RAB9AKDM4EMAPK8MAPK10 | |
| SCHEMBL17411217 | 0.79 | GPR119 (0.47) | NPC1RAB9AKDM4EMAPK8MAPK10 | |
| SCHEMBL27086563 | 0.79 | GPR119 (0.47) | NPC1RAB9AKDM4EGPR119PDE8B | |
| SCHEMBL25447242 | 0.78 | CHRM4 (0.42) | NPC1RAB9AKDM4EMAPK8MAPK10 | |
| SCHEMBL25190421 | 0.78 | SMO (0.40) | NPC1RAB9AKDM4EMAPK8MAPK10 | |
| SCHEMBL10243308 | 0.75 | KDM4E (0.51) | KDM4EGPR119SMO | |
| SCHEMBL22526350 | 0.75 | RORC (0.45) | — | |
| SCHEMBL1621687 | 0.75 | MAPT (0.47) | NPC1RAB9AKDM4EOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPC1 2404/4885RAB9A 2340/4885KDM4E 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.